[Urinary 11-dehydro thromboxane B2 during toxemic pregnancies]

Area of Science:

• Biochemistry
• Reproductive Medicine
• Analytical Chemistry

Context:

• Toxemic pregnancies exhibit an imbalance in arachidonic acid metabolism, with increased thromboxane A2 (TXA2) and decreased prostacyclin (PGI2).
• Traditional measurement of TXA2 production in vivo using Thromboxane (TX) B2 is complicated by its rapid decomposition to 11-dehydro TXB2 during blood sampling.
• Accurate assessment of TXA2 metabolite levels is crucial for understanding pregnancy complications.

Purpose:

• To establish a reliable radioimmunoassay (RIA) method for quantifying urinary 11-dehydro TXB2.
• To validate the accuracy of the new RIA method against gas chromatography-mass spectrometry (GC-MS).
• To investigate the levels of urinary 11-dehydro TXB2 in normal and toxemic pregnancies and their correlation with blood pressure.

Summary:

• A novel RIA method using a highly specific antibody and an 125I-labeled kit was developed to measure urinary 11-dehydro TXB2.
• The RIA method demonstrated a high correlation (r = 0.95) with GC-MS, confirming its accuracy.
• Urinary 11-dehydro TXB2 levels increased progressively during normal pregnancy trimesters but were significantly lower in toxemic pregnancies compared to normal pregnancies.
• A significant negative correlation was observed between urinary 11-dehydro TXB2 concentration and blood pressure (p < 0.0001).

Impact:

• Provides a validated and accurate method for assessing in vivo TXA2 production via urinary 11-dehydro TXB2 measurement.
• Highlights a potential biomarker for diagnosing and monitoring toxemic pregnancies.
• Suggests a link between altered arachidonic acid metabolism, specifically reduced TXA2 activity, and the pathophysiology of preeclampsia.